Clinical Trial Begins For PolyActiva Biodegradable Glaucoma Implant. PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently received USD$12million in venture capital to fund its Phase 1 Clinical Trial which will evaluate the safety and tolerability of its PA5108 ocular implant designed to biodegrade after the treatment period.
An exciting new class of potential glaucoma medications include what are termed the ROCK and ROCK/NET inhibitors. And it’s about time! Twenty years have passed since the last new class of medications (prostaglandin analogs) were approved for the treatment of glaucoma.